Latest Mergers And Acquisitions News

Cluey Ltd reported a 50% improvement in EBITDA and its first positive operating cash flow quarter in FY25, driven by cost efficiencies and a return to student growth. The company is now pivoting towards AI-enabled product innovation to fuel sustainable expansion.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Jupiter Mines Limited reported a modest rise in net profit to $40.1 million for FY2025, supported by strong joint venture earnings and increased marketing fees. The company declared a final dividend as manganese prices stabilized after early-year volatility.

Cluey Ltd has marked a pivotal year with a $4.4 million EBITDA improvement and its first positive operating cash flow quarter, alongside renewed student growth. The company is now pivoting towards AI-driven product expansion to sustain momentum.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

AF Legal Group has reported a strong FY25 with 27% revenue growth and a 77% increase in normalised profit, driven by strategic acquisitions and operational improvements.

Boss Energy reports a strong financial foundation with positive operating cash flow and a robust balance sheet in FY2025, its first full year of uranium production. Despite a net loss driven by non-cash costs, the company positions itself for growth amid rising uranium prices.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.